Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 27;4(3):740-50.
doi: 10.3390/metabo4030740.

Applying metabolomics to understand the aggressive phenotype and identify novel therapeutic targets in glioblastoma

Affiliations
Review

Applying metabolomics to understand the aggressive phenotype and identify novel therapeutic targets in glioblastoma

Kamran A Ahmed et al. Metabolites. .

Abstract

Glioblastoma continues to be an invariably fatal malignancy. The established approach for understanding the biology of these aggressive tumors in an effort to identify novel molecular targets has largely been genotype-based. Unfortunately, clinical gains offered by this level of understanding have been limited, largely based on the complex nature of signaling networks associated with tumorigenesis and the inability to delineate the key "functional" signaling pathways actually driving growth in an individual tumor. Metabolomics is the global quantitative assessment of endogenous metabolites within a biological system, taking into account genetic regulation, altered kinetic activity of enzymes, and changes in metabolic reactions. Thus, compared to genomics and proteomics, metabolomics reflects changes in phenotype and therefore function. In this review, we highlight some of the key advancements that have been made in applying metabolomics to understand the aggressive phenotype of glioblastoma. Collectively, these studies have provided a previously unrecognized window into the underlying biology of these tumors. Current and future efforts are designed to determine how this technology may be applied to improve diagnosis and predict the aggressiveness of glioblastoma, and more importantly, identify novel, therapeutic strategies designed to improve clinical outcomes.

PubMed Disclaimer

References

    1. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-year analysis of the eortc-ncic trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7. - DOI - PubMed
    1. TCGA Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. doi: 10.1038/nature07385. - DOI - PMC - PubMed
    1. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer. 2004;4:551–561. doi: 10.1038/nrc1390. - DOI - PubMed
    1. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: A review. Clin. Res. Canc. 2009;15:431–440. doi: 10.1158/1078-0432.CCR-08-1059. - DOI - PMC - PubMed
    1. Bathen T.F., Jensen L.R., Sitter B., Fjosne H.E., Halgunset J., Axelson D.E., Gribbestad I.S., Lundgren S. Mr-Determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res. Treat. 2007;104:181–189. doi: 10.1007/s10549-006-9400-z. - DOI - PubMed

LinkOut - more resources